Insilico Medicine has commenced its initial public offering (IPO) on the Hong Kong Stock Exchange (HKEX), with share subscriptions accepted from 18 to 23 December. The company plans to issue 94.69 million shares at an indicative price of HKD 24.05 (USD 3.09) per share, aiming to raise capital in what is projected to be the largest biotech IPO on the Hong Kong market in 2025. Trading is expected to begin on 30 December. The offering is supported by a consortium of 15 cornerstone investors who have subscribed for USD 115 million in shares, featuring a notable mix of strategic and financial backers.

The list includes Eli Lilly, making its debut as a biotech IPO cornerstone investor, and Tencent, representing a significant strategic investment from the technology sector. This diverse investor base underscores broad confidence in Insilico's AI-driven drug discovery platform, which has generated a pipeline of over 30 programs and secured partnerships with 13 of the world's top 20 pharmaceutical companies.

PharmCube's NextBiopharm® database shows that Insilico's assets sell for hundreds of millions of USD, according to transactions with disclosed data. Click here to request a free trial for NextBiopharm®.